Anti-β2 GPI/HLA-DR antibodies may define a distinct subset of women with recurrent pregnancy loss, offering both diagnostic utility in seronegative APS and potential targets for novel therapies [52]. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.